The recent phase I study of tinengotinib, a multiple kinase inhibitor, as a single agent in patients with advanced solid tumors showed that tinengotinib was well tolerated and indicated potential clinical benefit in FGFR inhibitor-refractory cholangiocarcinoma, HER2-negative breast cancer (including triple-negative breast cancer), and castration-resistant prostate cancer. This evidence concerns the gene ERBB2 and triple-negative breast carcinoma.